Related Experiment Videos
Diagnosing human parvovirus B19 infection: guidelines for test selection
1University of Pittsburgh, Magee-Women's Research Institute, Pittsburgh, PA 15213, USA. jordanja+@pitt.edu
Insights
Human parvovirus B19 causes a common childhood illness. Choosing the right diagnostic test, like serology or molecular assays, is crucial for accurate parvovirus B19 diagnosis and patient care.
Area of Science:
- Virology
- Immunology
- Pediatrics
Background:
- Human parvovirus B19 is a common cause of childhood illness with a typically mild course.
- Viral replication targets erythroid precursor cells expressing the globoside receptor.
- Certain populations, including those with shortened red blood cell half-lives, immunocompromised individuals, pregnant women, and fetuses, are at higher risk for severe complications.
Purpose of the Study:
- To emphasize the importance of selecting appropriate diagnostic tests for human parvovirus B19.
- To guide clinicians in choosing between serological testing and molecular amplification assays based on patient status.
Main Methods:
- Review of diagnostic strategies for human parvovirus B19 detection.
- Analysis of patient-dependent factors influencing test selection.
- Comparison of serological assays and molecular amplification assays.
Main Results:
- Serological testing is recommended for immunocompetent individuals with symptoms or exposure history.
- Molecular amplification assays are indicated for patients with inadequate antibody responses.
- Inappropriate test selection can lead to misinformation and misdiagnosis.
Conclusions:
- Clinician education on appropriate parvovirus B19 diagnostic testing is critical.
- Patient-specific factors dictate the choice between serological and molecular tests.
- Accurate diagnosis of parvovirus B19 infection relies on judicious test selection.
Abstract:
Human parvovirus B19 is the cause of a common childhood disease that usually has a mild and self-limited course. Complete viral replication and subsequent cell lysis are limited to early erythroid precursor cells expressing the globoside receptor. Individuals with shortened red blood cell half-lives and immunocompromised or immunosuppressed patients, as well as pregnant women and developing fetuses, are at risk for severe anemia and/or persistent infection from human parvovirus B19. Selection of the diagnostic test(s) to use to detect parvovirus B19 is patient dependent. Serological testing is most appropriate in immunocompetent individuals, including children and pregnant women, who have symptoms consistent with parvovirus B19 infection or a history of recent exposure. Conversely, a molecular amplification assay should be chosen to detect parvovirus B19 DNA in individuals lacking an adequate antibody-mediated immune response. In summary, it is critical that clinicians are educated about the most appropriate diagnostic test to detect parvovirus B19 infection in their patients because selecting an inappropriate or inaccurate test for parvovirus B19 can lead to misinformation and/or misdiagnosis.